amgen

Despite declining ESA sales and full HC reform impact, Amgen (NASDAQ: AMGN) expects flat to ~3% revenue growth y/y in 2011 (largely supported by Prolia/XGEVA), Jefferies reports. “On inexpensive valuation (~11x '11 earnings vs. ~14x peers), strong FCF yields (~10%) and potential dividend payout, we...

Contrary to expectations, Goldman Sachs reports that XGEVA met its primary endpoint in the Phase III trial of metastasis prevention in prostate cancer. As a result, Amgen Inc. (NASDAQ: AMGN) could trade up 5%-8%, Goldman Sachs believes. “But we expect the upside to be short-lived, as (1) the data...

Oppenheimer is out with a report on Amgen (NASDAQ: AMGN), following Amgen's Xgeva results. In a note to clients, Oppenheimer writes, "AMGN announced Xgeva (denosumab) delayed bone mets in patients with advanced prostate cancer (PC) in the ph.III '147 trial. We view these results as clearly...

J.P. Morgan is reiterating its Overweight rating on shares of Amgen Inc. (NASDAQ: AMGN). “Based on Xgeva survey results, lowered 2011 Street expectations for Prolia/Xgeva and low expectations for legacy products, we remain buyers of AMGN shares,” J.P. Morgan writes. “Additionally, we believe there...

Amgen (NASDAQ: AMGN) is downgraded from Outperform to Market Perform at MP Advisors. Price target has decreased from $65 to $63.

Deutsche Bank has published a research report on Amgen, Inc. (NASDAQ: AMGN) after the company's report in the Journal of Clinical Oncology. In the report, Deutsche Bank writes "This evening, the complete ph 3 results from the Dmab SRE breast cancer trial were published in the Journal of Clinical...

Oppenheimer has published a research report on Amgen Inc. (NASDAQ: AMGN) following an FDA panel discussion on the potential restriction of Arenesp based on safety findings. In the report, Oppenheimer writes "As we had expected, the panel voted against removing Aranesp's indication for treatment of...